CareNavigator

New Zealand Cancer Patients in China

Important: This article is for informational purposes only and does not constitute medical advice. ACC and PHARMAC rules are complex and subject to change; patients should confirm current requirements with the relevant New Zealand authority and their treating clinician.

Why Are New Zealand Cancer Patients Increasingly Looking at Treatment in China?

For many New Zealand families facing a cancer diagnosis, the public health system provides a solid foundation — but it has limits. When cancer is aggressive, rare, or has stopped responding to standard treatment, some Kiwi patients find themselves asking a question that would have seemed unthinkable a decade ago: Could treatment in China be the right next step?

This article walks through the reality of that decision — what treatments are available in China that New Zealand's public system currently limits or doesn't offer, how the funding landscape works (and doesn't work) for NZ citizens, what real patients have experienced, and how CareNavigator helps families navigate the entire process.

The Gap Between NZ's Public Cancer Treatment Options and Demand

New Zealand's public cancer treatment system is functional for standard care pathways. Chemotherapy, surgery, and radiation are publicly funded for most cancer types. However, several structural constraints create a growing treatment gap for patients with advanced or less common cancers:

These factors combine to make overseas treatment a rational consideration for some NZ patients — particularly those with advanced, rare, or relapsed cancers where time is not a luxury they can afford to spend waiting.

Which Cancer Types Are NZ Patients Seeking Abroad? CAR-T, Proton, Immunotherapy

The treatments NZ patients most commonly seek in China fall into three categories:

CAR-T Cell Therapy

New Zealand has no CAR-T program in its public system. For patients with relapsed or refractory B-cell lymphomas, leukaemia, or myeloma, CAR-T therapy is simply not available domestically without paying privately at enormous cost elsewhere. China has multiple NMPA-approved CAR-T products and active clinical trial programs — at a fraction of the US cost. For these patients, China represents a genuinely accessible option that does not exist within NZ's borders.

Proton Therapy

NZ has no proton therapy centre. For paediatric brain tumours, head and neck cancers (especially nasopharyngeal carcinoma), and sarcomas, proton therapy offers significant clinical advantages over conventional radiation. Australia has limited proton capacity, but access for NZ citizens is complicated — and Australia is not the only consideration. China now operates multiple operational proton centres with established international patient programs, including centres in Shanghai and Guangzhou that have treated paediatric patients from international backgrounds.

Advanced Immunotherapy and Targeted Therapy

PD-1/PD-L1 inhibitors are partially funded by PHARMAC but only for specific cancer indications. Patients whose cancer type does not meet current PHARMAC criteria must either pay privately or seek treatment abroad. China's National Medical Products Administration (NMPA) has approved many PD-1 inhibitors and targeted therapies in recent years, often ahead of NZ's approval timelines. Combination immunotherapy protocols — such as PD-1 combined with chemotherapy, or dual checkpoint inhibition — that are routinely used in Chinese cancer centres may not yet be standard in New Zealand.

What Cancer Treatments Are Available in China That NZ's Public System May Not Cover?

CAR-T Cell Therapy — Not Currently Available in NZ's Public System

CAR-T therapy re-engineers a patient's own immune cells to recognise and attack cancer. It has transformed outcomes for patients with certain blood cancers who have exhausted standard treatment options. In New Zealand, the pathway is clear: CAR-T is not publicly funded for most patients. Private treatment elsewhere costs over half a million US dollars. China has made CAR-T more accessible through domestic manufacturing and clinical trial programs, with treatment costs that are a fraction of US pricing. A NZ patient whose options are exhausted domestically has a meaningfully different equation presented to them when China is added as a consideration.

Proton Therapy — NZ Has No Proton Centre; Australia Funding Available but Limited

Proton therapy is the standard of care for many paediatric brain tumours and several adult cancers in many countries. NZ has no proton facility. Australia's Medical Treatment Overseas (MTO) program has historically approved some paediatric proton cases, but this program is for Australian citizens and permanent residents only — NZ citizens do not qualify. China's proton centres, particularly those with international patient programs, have emerged as a practical alternative for NZ families. This is discussed further in the funding section below.

Advanced Immunotherapy and Targeted Therapy Access in China

China's domestic pharmaceutical industry has grown rapidly, producing multiple biosimilar and novel immunotherapy drugs now accessible to international patients being treated in Chinese hospitals. PD-1 inhibitors such as toripalimab, camrelizumab, and sintilimab — widely used in Chinese oncology — have demonstrated clinical activity across multiple cancer types. For NZ patients whose PHARMAC coverage does not extend to these drugs for their specific indication, accessing them in China may be the most viable pathway.

Real Stories — New Zealand Patients Who Traveled to China for CAR-T and Advanced Oncology

Patient stories documented in NZ journalism provide important E-E-A-T signals and illustrate the human reality behind the statistics. These are shared as patient experience illustrations, not as clinical evidence.

Case Reference: NZ Patient's CAR-T Experience (RNZ and CGTN, 2025)

Radio New Zealand reported in 2025 on the story of a NZ father with blood cancer who travelled to China for CAR-T cell therapy after being told his treatment options were exhausted in New Zealand. The report documented the process of obtaining a medical visa, coordinating with a Chinese hospital, and the clinical outcome — providing a publicly available, independently reported account of the patient journey.

CGTN, China's state international broadcaster, has covered international patients — including patients from New Zealand — travelling to China for advanced oncology. These first-hand accounts describe the practical realities of medical travel: language considerations, hospital choice, discharge processes, and the experience of returning home.

A Newsroom NZ report, "The NZ-Australia Blood Cancer Divide" (May 2026), documented the disparity in access to advanced blood cancer treatments between Australia and New Zealand — and the growing trend of NZ patients seeking treatment across the Tasman and beyond. While Australia has a government-funded MTO program, New Zealand has no equivalent, making the decision to travel abroad more clearly a self-funding decision for most NZ families.

What Families Learned About Coordination, Cost, and Follow-Up

Families who have navigated this path report that the three most challenging aspects are: medical record translation and compilation, visa processing, and coordinating follow-up care with NZ healthcare providers after returning home.

Cost was less of a shock than expected for many families — particularly for CAR-T, where the China cost was 20–30% of the US equivalent even after all travel expenses included. However, follow-up care coordination is critical: the discharge summary from the Chinese hospital must be detailed enough for an NZ oncologist to seamlessly continue care. Families who had dedicated coordinators reported significantly less stress throughout the process.

How the Medical Treatment Overseas Program (MTO) Works — And Whether It Covers China

Important distinction — New Zealand vs. Australia: New Zealand does not have a government-funded Medical Treatment Overseas Program equivalent to Australia's MTO. This is one of the most important differences between the two countries' healthcare systems when it comes to overseas treatment access.

Australia's MTO Program (For Australian Patients Only)

Australia's Medical Treatment Overseas Program (MTO) is a government initiative that helps fund Australian citizens and permanent residents to travel overseas for treatment not available in Australia. The program has historically approved some cases involving paediatric proton therapy and other advanced treatments.

New Zealand patients are not eligible for Australia's MTO. This is a common point of confusion — the program is not available to NZ citizens, even when travelling to the same countries. Our guide to Australia's MTO program covers the pathway in full detail.

ACC (Accident Compensation Corporation)

ACC is a New Zealand government no-fault accident insurance scheme. For some cancer types where the cancer is linked to a covered accident or injury — such as certain occupational exposures — ACC may provide cover for overseas treatment. However:

NZ Government Funding — No Formal Overseas Cancer Treatment Program

As of 2026, no New Zealand government program specifically funds cancer treatment in China or other overseas destinations for NZ citizens. Some NZ oncologists may write letters of support for patients seeking treatment abroad, but this does not guarantee funding from any NZ government source. PHARMAC funds medicines for NZ residents within New Zealand only — it does not fund overseas treatment unless specifically approved through a named patient process, which is rare.

Private Health Insurance

Some NZ patients hold private health insurance policies that include international treatment coverage. If your policy includes this, review the terms carefully — some insurers require pre-approval, may cap overseas treatment benefits, and may require the treating facility to meet specific accreditation standards. Check with your insurer before committing to any overseas treatment plan.

Self-Funding

Most NZ patients travelling to China for cancer treatment are self-funding. This is why cost transparency is a key part of the CareNavigator value proposition — we help families understand the full cost picture, including treatment, travel, accommodation, and follow-up coordination, before they make any commitments.

What NZ Oncologists Need to Know Before You Travel

Being transparent with your NZ oncologist is strongly recommended — they are part of your care team, and their buy-in makes the entire process smoother and safer.

How to Have the Conversation With Your Oncologist

Approach the conversation as a collaborative decision rather than a unilateral one. Suggested framing: "I'm looking at all my options and wanted to keep you informed and involved." Specific questions worth asking:

  1. Do you have any concerns about my current treatment plan?
  2. Would you support me in seeking a second opinion from a specialist in China?
  3. Can you provide a referral letter and assist with transferring my medical records?
  4. What is your experience with [specific treatment type]?
  5. Would you be willing to coordinate with a Chinese hospital on my follow-up care if I travel?

Most NZ oncologists will appreciate being informed and included rather than surprised after the fact. Many have limited familiarity with China's oncology capabilities — offering to share information about the specific treatment and centre you're considering can help them engage more constructively.

Letters of Support and Clinical Documentation

A letter from your NZ oncologist confirming your diagnosis, treatment history, and current clinical status is one of the most useful documents for a Chinese hospital's international patient department. It provides clinical credibility and helps the Chinese specialist understand your case more quickly. If your oncologist is reluctant to provide records, you have the right to request them transferred to another physician under New Zealand's Health Information Privacy Act.

How to Plan for Follow-Up Care Back in New Zealand After Treatment in China

This is one of the most common concerns families raise — and one of the most important practical steps in the entire process.

Discharge Summary Requirements for NZ Healthcare Providers

Before leaving China, request a comprehensive discharge summary in English. The discharge summary must include:

Many NZ GPs and oncologists are unfamiliar with treatments like CAR-T or proton therapy. The discharge summary should be detailed enough that your NZ doctor can confidently continue your care without needing to re-investigate your case from scratch.

Coordinating Ongoing Treatment Plans With Your NZ GP or Oncologist

Before you leave China, ask the Chinese hospital's international patient coordinator to send a copy of your records directly to your NZ oncologist or GP. Schedule a follow-up appointment with your NZ oncologist for within 1–2 weeks of your return. Bring physical copies of all reports — do not rely on digital delivery alone. Ask the Chinese treating team whether they are available for direct communication with your NZ oncologist if clinical questions arise during your recovery.

How CareNavigator Helps NZ Families Navigate Treatment Decisions

CareNavigator provides NZ families with a dedicated coordinator who understands the specific challenges of navigating two health systems from a distance — including timezone differences, medical record logistics, visa requirements, and cultural communication.

Our role is to help you understand whether China is genuinely the right option for your specific cancer type and clinical situation, or whether your needs are better served through other pathways. We handle the logistics: hospital selection, record compilation, visa assistance, accommodation planning, and follow-up coordination. Critically, we maintain clinical neutrality — we do not push travel if a remote second opinion indicates that your current treatment plan is already optimal.

Getting started is simple. Book your $29 Initial Strategy Call — this is the primary first step for any NZ family wanting to understand their options. During the call, we'll review your situation, answer your specific questions, and help you understand what a pathway to treatment in China would look like for your case.

If your family is considering whether treatment in China is realistic, start with a short strategy call to review your situation and the questions that need answering first.<br/><a href="/services">Book Your Initial Strategy Call — USD 29</a>

Frequently Asked Questions

Q1: Does New Zealand's public healthcare system cover CAR-T cell therapy?

No. As of 2026, CAR-T cell therapy is not publicly funded in New Zealand's health system for most patients. Private CAR-T treatment in other countries costs USD $400,000–$500,000+, making it effectively inaccessible for most NZ patients without significant personal resources. This is one of the primary reasons NZ patients are considering CAR-T options in China, where treatment costs are significantly lower.

Q2: What is the Medical Treatment Overseas Program (MTO) and can NZ patients use it for treatment in China?

Australia's MTO is a government program that funds Australian citizens and permanent residents to travel overseas for treatment not available in Australia. New Zealand patients are not eligible for Australia's MTO — it is not available to NZ citizens. New Zealand does not have an equivalent government program specifically funding overseas cancer treatment. Most NZ patients travelling to China for cancer treatment are self-funding or relying on private health insurance.

Q3: What cancer treatments are available in China that may not be accessible in NZ?

The treatments most commonly accessed by NZ patients in China include CAR-T cell therapy for blood cancers (not publicly funded in NZ), proton therapy for paediatric brain tumours and head/neck cancers (NZ has no proton centre), and advanced immunotherapy and targeted therapies that may not yet be approved or funded by PHARMAC in NZ. China's high-volume cancer centres also offer deep expertise in rare cancer types that NZ oncologists may see only a handful of cases of per year.

Q4: How do I plan for follow-up care after returning to New Zealand from cancer treatment in China?

Before leaving China, request a comprehensive English-language discharge summary from the hospital including your full treatment protocol, response to treatment, any complications, and a detailed follow-up care plan. Share this with your NZ oncologist or GP before your first follow-up appointment. Schedule a follow-up appointment with your NZ oncologist within 1–2 weeks of your return. Ask the Chinese hospital whether their team is available to communicate directly with your NZ doctor if questions arise during your recovery.

Q5: What questions should I ask my NZ oncologist before deciding to travel to China for treatment?

Key questions include: (1) Do you have any concerns about my current treatment plan? (2) Would you support me in seeking a second opinion from a specialist in China? (3) Can you provide a referral letter and transfer my medical records? (4) What is your experience with [specific treatment type]? (5) Would you be willing to coordinate with a Chinese hospital on my follow-up care if I travel? Most NZ oncologists will appreciate being informed and included in the decision process rather than surprised after the fact.

This article was last updated June 03, 2026. The content is informational only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions. CareNavigator services are subject to terms and conditions.

References & Source Notes

Back to CareNavigator Insights